Key Financial Data Of Reporting Company

BrightPath Biotherapeutics Co., Ltd. - Filing #7302244

Concept 2024-04-01 to
2024-09-30
As at
2024-09-30
As at
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2023-09-30
As at
2023-09-30
Key financial data of reporting company
Business results of reporting company
Net sales
56,000 JPY
72,000 JPY
44,000 JPY
Ordinary profit (loss)
-537,786,000 JPY
-1,158,929,000 JPY
-551,566,000 JPY
Profit (loss)
-538,736,000 JPY
-1,168,082,000 JPY
-553,922,000 JPY
Equity in earnings (losses) of affiliates if equity method is applied
JPY
JPY
JPY
Share capital
1,047,921,000 JPY
650,661,000 JPY
362,185,000 JPY
Total number of issued shares
83,791,300 xbrli:shares
70,741,300 xbrli:shares
62,891,200 xbrli:shares
Net assets
1,234,107,000 JPY
978,987,000 JPY
1,013,618,000 JPY
Total assets
1,696,224,000 JPY
1,230,257,000 JPY
1,163,667,000 JPY
Dividend paid per share
Basic earnings (loss) per share
-7.11
-18.21
-8.81
Diluted earnings per share
Equity-to-asset ratio
0.714 xbrli:pure
0.777 xbrli:pure
0.854 xbrli:pure
Net cash provided by (used in) operating activities
-520,584,000 JPY
-1,156,920,000 JPY
-466,327,000 JPY
Net cash provided by (used in) investing activities
JPY
-7,648,000 JPY
-1,454,000 JPY
Net cash provided by (used in) financing activities
1,002,619,000 JPY
690,959,000 JPY
JPY
Cash and cash equivalents
1,539,394,000 JPY
1,057,360,000 JPY
1,063,188,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.